Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial. [electronic resource] by
- Correale, Pierpaolo
- Botta, Cirino
- Rotundo, Maria S
- Guglielmo, Annamaria
- Conca, Raffaele
- Licchetta, Antonella
- Pastina, Pierpaolo
- Bestoso, Elena
- Ciliberto, Domenico
- Cusi, Maria G
- Fioravanti, Antonella
- Guidelli, Giacomo M
- Bianco, Maria T
- Misso, Gabriella
- Martino, Elodia
- Caraglia, Michele
- Tassone, Pierfrancesco
- Mini, Enrico
- Mantovani, Giovanni
- Ridolfi, Ruggero
- Pirtoli, Luigi
- Tagliaferri, Pierosandro
Producer: 20140718
In:
Journal of immunotherapy (Hagerstown, Md. : 1997) vol. 37
Availability: No items available.
|